1. Santos-García D, Llaneza M, Abella J, Aneiros A, Santos H, Macías M.

Estudios
neurofisiológicos en los parkinsonismos. Rev Neurol 2012; 54 (Supl 4): S13-22.
2. Abdo, Wilson & P C van de Warrenburg, Bart & Burn, David & P Quinn, Niall &
Bloem, Bas. (2010). The clinical approach to movement disorders. Nature reviews.
Neurology. 6. 29-37. 10.1038/nrneurol.2009.196.
3. Jiménez-Jiménez, F. J., Alonso-Navarro, H., Luquin, M. R. & Burguera, J. A.
(2015). Trastornos del movimiento (I): conceptos generales, clasificación de los
síndromes parkinsonianos y enfermedad de Parkinson. Medicine, 11(74), 4415-26.
4. Rodríguez Montalbán M, Gámez Rodríguez O, Hernández Silva T, Echavarría
Danger S, Bizet Altes O. Morbilidad por trastornos del movimiento en la consulta
de Neurología. Medisan 2012; 16(5):727-35.
5. Williams, D. & Litvan, I. (2013). Parkinsonian Syndromes. Contimuum (Minneap
Minn) 19(5), 1189-1212.
6. Caballero Duque, Andrea, & Zuluaga Sánchez, Isabel Cristina. (2007). Síntomas
psiquiátricos de la parálisis supranuclear progresiva. Revista Colombiana de
Psiquiatría, 36(4), 772-779.
7. Gil-Alzueta MC, Erro-Aguirre ME. Parálisis supranuclear progresiva. Rev Neurol
2012; 54 (Supl 4): S53-8.
8. Stamelou M., Oertel W.H. (2017) Progressive Supranuclear Palsy. En: Falup-
Pecurariu C., Ferreira J., Martinez-Martin P., Chaudhuri K. (eds) Movement
Disorders Curricula. Springer, Vienna.
9. Vaughan C Ly Goetz C, Progressive Supranuclear Palsy (PSP), En Encyclopedia of
the Neurological Sciences (Second Edition), Academic Press, Oxford, 2014, pág
987-988.
10. Barquero MS, Dominguez M. Demencia en pacientes con parálisis supranuclear
progresiva. Rev Neurol 2001; 32 (11):1071-1073.
11. Miranda-Siveloa, A., Cámara-Barrioa, S., Martín-Polo, J. Aspectos
neuropsiquiátricos de la parálisis supranuclear progresiva: análisis de un caso.
Psiquiatría Biológica. 2012; 19(S1):62–64.
12. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of
progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of
the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9.
13. Caballero Duque, Andrea, & Zuluaga Sánchez, Isabel Cristina. (2007). Síntomas
psiquiátricos de la parálisis supranuclear progresiva. Revista Colombiana de
Psiquiatría, 36(4), 772-779.
14. L Boxer, Adam & Yu, Jin-Tai & I Golbe, Lawrence & Litvan, Irene & E Lang,
Anthony & Höglinger, Günter. (2017). Advances in progressive supranuclear palsy:
new diagnostic criteria, biomarkers, and therapeutic approaches. The Lancet
Neurology. 16. 552-563. 10.1016/S1474-4422(17)30157-6.
15. Golbe L. Progressive Supranuclear Palsy. Semin Neurol 2014; 34(02): 151-159.
16. Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, eds. Bradley's Neurology in
Clinical Practice. 7th ed. Philadelphia, PA: Elsevier; 2016.
17. Moccia M, Picillo M, Erro R, et al. Presence and progression of non-motor
symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol
2015; 22:93-98.
18. Oropesa Ruíz, J, Huertas-Fernandez I, Jesus S, Caceres-Redondo M, Vargas-
Gonzalez, M, Carrillo F, Carballo M et al. Low Serum Uric Acid Levels in
Progressive Supranuclear Palsy. Movement Disorders 2016, 31 (3).
19. Sánchez-Jordán, A., Martínez-López, Y., Boll, M. (2013). Diagnóstico clínico de
atrofia de múltiples sistemas en una serie de casos. Arch Neurocien (Mex), 18 (1):
10-14.
20. Fanciulli, A., Wenning, G., (2015). Multiple-System Atrophy. The New England
Journal of Medicine, 372 (3): 249-263.
21. Laurens, B., Vergnet, S., Lopez, M., Foubert-Samier, A., Tison, F., Fernagut, P.,
Meissner, W. (2017). Multiple System Atrophy - State of the Art. Curr Neurol
Neurosci Rep. 17 (41): 41-51
22. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK (2012) Premotor signs and
symptoms of multiple system atrophy. Lancet Neurol, 11:361-8.
23. Segarra AB, Banegas I, Prieto I, Ramírez-Sánchez M. Asimetría cerebral y
dopamina: más allá de las implicaciones motoras en la enfermedad de Parkinson y
hemiparkinsonismo experimental. Rev Neurol 2016; 63: 415-21.
24. Lin DJ, Hermann KL, Schmahmann JD. Multiple system atrophy of the cere- bellar
type: clinical state of the art. Mov Disord 2014; 29:294-304.
25. Gilman S., Wenning G., Low P., Brooks D., Mathias C. (2008). Second consensus
statement on the diagnosis of multiple system atrophy. Neurol. 71:670-6.
26. FALTA
27. Peñas-Martínez M, HerreroVelázquez S, Cortijo-García E, Mulero P, Marco-
Llorente J. Degeneración corticobasal. Rev Neurol 2012; 54 (Supl 4): S59-66.
28. Donoso, A., Miranda, M., Díaz, M., Silva, C., y Vásquez, C. Degeneración
corticobasal: 5 casos clínicos. Revista Chilena de Neuropsiquiatría (2003), 41(3),
191-200.
29. M.J. Armstrong, I. Litvan, A.E. Lang, T.H. Bak, K.P. Bhatia, B. Borroni , A.L.
Boxer, D.W. Dickson, M. Grossman, M. Hallett, K.A. Josephs, A. Kertesz, S.E.
Lee, B.L. Miller, S.G. Reich, D.E. Riley, E. Tolosa, A.I. Tröster, M. Vidailhet ,
W.J. Weiner, Criteria for the diagnosis of corticobasal degeneration, Neurology. 80
(2013) 496–503.
30. Colosimo, C., Marsili, L., Suppa, A., Berardelli, A. Therapeutic interventions in
parkinsonism: Corticobasal degeneration. Parkinsonism & Related Disorders, 22
(2016), pp 96-100.
31. Rinne JO,Lee MS,Thompson PD,Marsden CD. Corticobasal degeneration. A
clinical study of 36 cases. Brain, 117 (1994), pp. 1183-1196.
32. Whitwell JL, Schwarz CG, Reid RI, Kantarci K, Jack CR Jr, Josephs KA. Diffusion
tensor imaging comparison of progressive supranuclear palsy and corticobasal
syndromes. Parkinsonism and Related Disorders 2014; 20 (5) 493-498.
33. Burrell J, Hornberger M, Vucic S, Kiernan M, Hodges J. Apraxia and motor
dysfunction in corticobasal syndrome, PLoS One 9 (2014).
34. Poewe, W., Seppi, K., Tanner, C., Halliday, G., Brundin, P. Volkmann, J., Schrag,
A. & Lang, A. (2017). Parkinson Disease. Nature Reviews Disease Primers,
3(17013), 1-21
35. Rajput A, Rajput A. Parkinson’s disease management strategies. Expert Rev
Neurotherapeutics. 2006; 6:91-9.
36. Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T. D. (2014). The prevalence of
Parkinson’s disease: a systematic review and meta-analysis. Mov. Disord., 29,
1583–1590.
37. Instituto Nacional de Estadística y Geografía (INEGI). Encuesta Intercensal 2015.
Recuperado de http://www.beta.inegi.org.mx
38. Shahgholi, L., De Jesus, S., Wu, S. S., Pei, Q., Hassan, A., Armstrong, M. J., et al.
(2017). Hospitalization and rehospitalization in Parkinson disease patients: Data
from the National Parkinson Foundation Centers of Excellence. PLos ONE, 12(7).
doi: 10.1371/journal.pone.0180425.
39. Macleod, A. D., Taylor, K. S., & Counsell, C. E. (2014). Mortality in Parkinson's
disease: a systematic review and meta-analysis. Mov Disord, 29, 1615-22.
40. De Lau, L. M., Verbaan, D., Marinus, J., van Hilten, J. J. (2014). Survival in
Parkinson's disease. Relation with motor and non-motor features. Parkinsonism
Relat Disord, 20, 613-6.
41. Willis, A. W., Schootman, M., Kung, N., Evanoff, B. A., Perlmutter, J. S., Racette,
B. A. (2012). Predictors of survival in patients with Parkinson disease. Arch Neurol,
69, 601-7.
42. Juri C y Wanner V, Neuroimágenes de la Enfermedad de Parkinson: Rol de la
resonancia magnética, el SPECT y el PET. Revista Médica Clínica Las Condes
2016; 27:380-91.
43. Hughes A, et al. 2002. The accuracy of diagnosis of parkinsonian syndromes in a
specialist movement disorders service. En Santos-García D, Llaneza M, Abella J,
Aneiros A, Santos H, Macías M. Estudios neurofisiológicos en los parkinsonismos.
Rev Neurol 2012; 54 (Supl 4): S13-22.
44. Margarita Gómez-Chavarín, G. Roldan-Roldan, R. Morales-Espinosa , G. Pérez-
Soto, C., Torner-Aguilar. Mecanismos fisiopatológicos involucrados en la
enfermedad de Parkinson. Arch Neurocien (Mex) 2012; 17: 25-33.
45. Marinus J, Van Hilten JJ. The significance of motor asymmetry in Parkinson’s
disease. Mov Disord 2015; 30: 379-85.
46. Rodríguez Pupo, Jorge Michel, Díaz Rojas, Yuna Viviana, Rojas Rodríguez,
Yesenia, Ricardo Rodríguez, Yuniel, & Aguilera Rodríguez, Raúl. (2013).
Actualización en enfermedad de Parkinson idiopática. Correo Científico
Médico, 17(2), 163-177.
47. J, Jankovic. J Neurol Neurosurg Psychiatry. 2012; volumen (79).
DOI:10.1136/jnnp.2007.131045
48. Carlson, N. Fisiología de la conducta. (2006). Madrid: Pearson Educación. 6ta. Ed.
49. Hindle, J. Ageing, neurodegeneration and Parkinson’s disease. Age Ageing 2010;
39 (2): 156-161. DOI: https://doi.org/10.1093/ageing/afp223
50. De la Peña C, Fernández-Medina JM, Parra-Bolaños N, Martínez-Restrepo OA.
Estudio neuropsicológico en pacientes parkinsonianos: efectos de la estimulación
cerebral profunda. Rev Neurol 2016; 62: 152-6.
51. Raúl Martínez-Fernández., Carmen Gasca-Salas C., Álvaro Sánchez-Ferro, José
Ángel Obeso, ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON,
Revista Médica Clínica Las Condes, Volume 27, Issue 3, 2016, Pages 363-379.
52. FALTA
53. A. Fasano, L. M. Romito, A. Daniele et al., “Motor and cognitive outcome in
patients with Parkinson’s disease 8 years a er subthalamic implants,” Brain, vol.
133, no. 9, pp. 2664–2676, 2010.
54. M. G. Rizzone, A. Fasano, A. Daniele et al., “Long-term outcome of subthalamic
nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage
of the disease?” Parkinsonism and Related Disorders, vol. 20, no. 4, pp. 376–381,
2014.
55. Anderson, D., Grayson, B., Ba, F. Deep Brain Stimulation in Parkinson’s Disease:
New and Emerging Targets for Refractory Motor and Nonmotor Symptoms.
Parkinson’s Disease. 2017; 2017, (5124328). doi:10.1155/2017/5124328
56. FALTA
57. Krack P, Martinez-Fernandez R, Del Alamo M, Obeso JA. Current applications and
limitations of surgical treatments for movement disorders. Mov Disord 2017; 32:36-
52.
58. Hariz MI, Hariz GM. Therapeutic stimulation versus ablation. Handb Clin Neurol
2013; 116:63-71.
59. Ardian Hana, Georges Dooms, Hans-Schwarz y Frank Hertel. “Depiction of
dentatorubrothalamic tract fibers in patients with Parkinson’s disease and multiple
sclerosis in deep brain stimulation” BMC Research Notes (2016) 9: 345 DOI
10.1186 / s13104-016-2162-8.
60. Castro Toro, Aracelly, & Buriticá, Omar Freddy. (2014). Enfermedad de parkinson:
criterios diagnósticos, factores de riesgo y de progresión, y escalas de valoración del
estadio clínico. Acta Neurológica Colombiana, 30(4), 300-306.
61. Feliz-Feliz CE, García-Ruiz PJ, Del Val-Fernández J, Venegas-Pérez B, Bellido-
Cuéllar S, Aranda-Calleja MA. Enfermedad de Parkinson senil benigna. Rev Neurol
2017; 64: 575-6.
62. Quik, M., Bordia, T., Pérez, X. Nicotine as a Potential Neuroprotective Agent for
Parkinson’s Disease. Movement Disorders 2012; 27 (8).
63. Palacios N, Gao X, McCullough M, Schwarzschild M, Shah R, Gapstur S, Ascherio
A. Caffeine and risk of Parkinson disease in a large cohort of men and women. Mov
Disord. 2012. 1; 27(10): 1276–1282.
64. Qui, H., Li, S., Dose-response meta-analysis on coffee, tea and caffeine
consumption with risk of Parkinson's disease. Geriatr Gerontol Int. 2014
Apr;14(2):430-9.
65. Postuma R.B, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla
L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B. Caffeine for
treatment of Parkinson disease: A randomized controlled trial. Neurology 2012, 79
(7): 651-8.
66. Khan N, Mukhtar H. Tea and Health: Studies in Humans. Current pharmaceutical
design. 2013;19(34):6141-6147.
67. Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on
risk of Parkinson's disease in the Singapore Chinese Health Study. American
journal of epidemiology 2008; 167:553-60.